Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753850 | 0.76 | TSHR (0.46) | — | |
| SCHEMBL11243793 | 0.67 | GPR84 (0.44) | — | |
| SCHEMBL29440798 | 0.64 | GPR84 (0.44) | — | |
| SCHEMBL28380157 | 0.63 | HSD17B10 (0.38) | — | |
| SCHEMBL20968111 | 0.63 | LMNA (0.52) | — | |
| SCHEMBL25337536 | 0.63 | DNM1 (0.42) | — | |
| SCHEMBL25964870 | 0.63 | DNM1 (0.42) | — | |
| SCHEMBL25339758 | 0.63 | DNM1 (0.42) | — | |
| SCHEMBL27831391 | 0.62 | THRB (0.39) | MGLL | |
| SCHEMBL11484034 | 0.62 | AKR1B1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253296-B2 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2007-08-07 | — | — | US | disclosed |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | disclosed |
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2006-03-30 | — | — | US | disclosed |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | GENTIF (FR) | 2006-02-16 | — | — | US | disclosed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | disclosed |
| EP-1594486-A2 | USES OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME | Genfit (FR) | 2005-11-16 | — | — | EP | disclosed |
| EP-1592660-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | Genfit (FR) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004073593-A2 | USE OF ACYLATED AMINOPROPANEDIOLS AND SULPHUR AND NITROGEN ANALOGUES OF SAME FOR DIFFERENT THERAPEUTIC APPLICATIONS | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074239-A1 | ACYLATED AMINOPROPANEDIOLS AND ANALOGUES AND THERAPEUTIC USES THEREOF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | AASDHPPT, ABAT, AADAC | MGLL 2888/4885 |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | ASS1, SMURF1, SMURF2 | MGLL 767/4885 |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | AGPAT5, HAGH, AGPAT2 | MGLL 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.